BMY

Business profile & competitive position

Bristol-Myers Squibb Company (BMY) sits in the Healthcare sector, specifically the Drug Manufacturers - General industry. As a single-segment biopharmaceutical company, it discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines for serious diseases. Its therapeutic focus spans oncology, hematology, immunology, cardiovascular, and neuroscience, with products sold worldwide mainly to wholesalers, distributors, specialty pharmacies, and—less frequently—to retailers, hospitals, clinics, government agencies, and directly to patients.

The numbers suggest a business with meaningful pricing power and execution discipline, at least historically. A net margin of 18.9% and a return on equity of 46.8% are strong for any large-cap pharmaceutical, reflecting a portfolio of established, high-margin therapies and a capital structure that magnifies shareholder returns relative to equity. Those figures do not, by themselves, prove a durable moat—patent expirations and pipeline setbacks can erode both quickly in this industry—but they do indicate that BMY has been converting its marketed assets into substantial profits and efficiently deploying equity capital in the recent period.

Financial posture

At a market capitalization of $128.7 billion and a P/E ratio of 13.9, BMY carries a valuation discount to many large-cap peers in the drug-manufacturing space, where multiples frequently sit well into the high teens or above. That relatively modest P/E, combined with the 18.9% net margin and 46.8% ROE, can read as a classic “value with execution” profile: the market is paying less per dollar of earnings even though profitability metrics remain robust. The beta of 0.23 underscores low correlation with the broader market, which is typical for large pharmaceutical stocks but still worth noting for anyone sizing risk against a benchmark.

The financial snapshot as of September 21, 2026, shows the stock trading at $63.0075, with an RSI of 40.2 and a 50-day EMA of $63.65. Price is essentially hugging the moving average, while the RSI sits in neutral territory—neither oversold nor overbought. These technical levels do not imply any directional bias; they simply describe a stock that has spent recent sessions consolidating around its near-term average.

Strategic priorities & outlook

Bristol-Myers Squibb’s most recent 10-K filing lays out a clear set of near-term priorities. The company intends to focus on transformational medicines where it believes it holds a competitive advantage, drive operational excellence across the organization, allocate capital strategically for long-term growth and shareholder returns, and execute commercially around first-in-class and/or best-in-class marketed products.

The filing also highlights real operational scale and recent business-development activity. Total revenues came in at $48.194 billion in 2025, essentially flat versus $48.300 billion in 2024 and up from $45.006 billion in 2023. Geographic concentration is meaningful: 69% of 2025 revenue originated in the United States, 29% from international markets, and 2% from “Other” categories. R&D spending was $10.0 billion in 2025, down from $11.2 billion in 2024 but above the $9.3 billion spent in 2023, and the pipeline now includes over 45 unique assets in development. On the business-development front, 2025 included the acquisition of Orbital Therapeutics, a global strategic collaboration with BioNTech, and a global exclusive licensing agreement with Philochem. These moves align with the stated priority of capital allocation aimed at long-term growth.

Macro & geopolitical exposure

As a global drug manufacturer, BMY is exposed to the macro and policy currents that shape pharmaceutical markets. The most prominent is regulatory and reimbursement risk: drug pricing legislation, Medicare and Medicaid policy, and international reference-pricing regimes can compress realized prices for branded therapies. FDA approval timelines, labeling decisions, and post-market safety obligations also affect revenue visibility, especially for newer assets.

Trade policy and currency matter too. With 29% of revenue coming from international markets, a stronger U.S. dollar can reduce the dollar value of overseas sales, while tariffs or cross-border drug-export restrictions can disrupt distribution. Supply-chain exposure is inherent to the industry—active pharmaceutical ingredients, biologics manufacturing capacity, and cold-chain logistics can all be subject to geopolitical friction or regional disruptions, though the 10-K does not flag any company-specific bottlenecks. Finally, the broader healthcare sector is sensitive to legislative shifts around insurance coverage and government-funded research, both of which can alter demand dynamics for prescription drugs.

Recent developments

The latest headlines around BMY have leaned toward valuation and clinical optimism. On September 21, 2026, Zacks published two pieces: one asking “BMY vs GILD: Which Biotech Stock Looks More Attractive Now?” and another titled “Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term.” That same value theme appeared in a September 20, 2026, Fool.com article, “Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder.” Also on September 18, 2026, Zacks asked, “Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?,” pointing to a specific pipeline/commercial asset—Sotyktu in psoriatic arthritis—as a potential near-term catalyst. These articles collectively reflect a narrative around BMY as an undervalued large-cap pharma name with potential clinical upside, though headlines alone do not confirm outcomes.

Earnings behavior & post-earnings drift

BMY’s recent earnings record is nearly spotless on the headline beat count: over the last eight reported quarters, the company beat consensus EPS every time, for a 100% beat rate, with an average earnings surprise of 17.2%. The most recent four quarters illustrate how those beats have varied in magnitude. On July 30, 2026, BMY reported EPS of $2.04 versus an estimate of $1.60, a 27.5% surprise. On April 30, 2026, actual EPS was $1.58 against a $1.42 estimate, an 11.3% surprise. On February 5, 2026, EPS came in at $1.26 versus $1.23, a 2.4% surprise. And on October 30, 2025, BMY posted $1.63 versus $1.52, a 7.2% surprise. In each case, the company cleared the official estimate.

Yet price action has not followed the beat in a straightforward way. Across those same eight quarters, the average 5-day post-earnings move was -1.37%, classified as a down drift. The last four quarters show the same inconsistency. After the July 30, 2026 beat, the stock rose 0.69% the next day but fell 1.09% over the following five sessions. The April 30, 2026 beat was followed by a next-day drop of 3.91% and a five-day decline of 7.16%. The February 5, 2026 report produced a 4.15% next-day gain and a 0.57% five-day gain, while the October 30, 2025 beat saw a 0.99% next-day gain and a 2.21% five-day gain. The message is that beating the consensus has not reliably produced a pop-and-hold; in several cases, better-than-expected results were met with immediate selling or a drift lower.

This disconnect is important for anyone reading the 100% beat rate as a bullish signal in isolation. The market’s real expectation—the unofficial consensus built around guidance, pipeline data, and peer commentary—may have been higher than the published estimate, or investors may have used the event to take profits in a stock that already discounts strong execution. With the next earnings report scheduled for October 29, 2026, before the open, and the current consensus EPS estimate at $1.68, traders and investors will be watching not only whether BMY beats again, but how the market prices that beat relative to forward guidance and any updates on key assets like Sotyktu or the broader pipeline.

For a deeper dive into how institutional analysts are interpreting BMY's valuation, pipeline risk, and upcoming earnings setup on October 29, 2026, look at the full institutional verdict for a more complete picture.